Aligos Therapeutics【ALGS】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

18.15

買値

18.08

売値

18.20

出来高

101,917

17.55 日の範囲 18.43

6.76 52 週間の範囲 30.00

時価総額

65.12M

前日終値

18.20

始値

18.17

時刻

18.01

最終取引時間

00:12:22

財務取引量

US$ 1,828,527

VWAP

17.9413

平均取引量 (3 か月)

259,496

発行済株式数

3,587,892

配当利回り

PER

-0.74

1 株当たり利益 (EPS)

-24.44

歳入

15.53M

純利益

-87.68M

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.aligos.com

本社

Wilmington, Delaware, USA

設立

Aligos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker ALGS. The last closing price for Aligos Therapeutics was US$18.20. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 6.76 to US$ 30.00.

Aligos Therapeutics currently has 3,587,892 shares in issue. The market capitalisation of Aligos Therapeutics is US$65.30 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.74.

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient...

Form 8-K - Current report

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes...

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq:...

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.28	-6.58775090067	19.43	24.8372	14.65	700680	18.90195327	CS
4	10.99	153.491620112	7.16	24.8372	7.1001	591433	15.52219302	CS
12	5.07	38.7614678899	13.08	24.8372	6.76	259496	14.59382514	CS
26	1.1925	7.03228659885	16.9575	24.8372	6.76	323525	13.08682829	CS
52	1.2225	7.22197607444	16.9275	30	6.76	342621	16.5630796	CS
156	-383.1	-95.476635514	401.25	416.5	6.76	276127	42.00440107	CS
260	-350.35	-95.0746268657	368.5	937.7475	6.76	248964	126.6931332	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
SKKSKK Holdings Limited	US$ 10.86 (138.16%)	2.68M
WORXSCWorx Corporation	US$ 2.15 (119.39%)	80.83M
CRNCCerence Inc	US$ 4.50 (59.57%)	7.99M
SPAISafe Pro Group Inc	US$ 4.3999 (37.50%)	34M
CDTConduit Pharmaceuticals Inc	US$ 0.1243 (34.67%)	405.44M
PYXSPyxis Oncology Inc	US$ 2.0101 (-47.38%)	6.59M
KURAKura Oncology Inc	US$ 10.02 (-37.02%)	5.21M
BLRXBioLineRx Ltd	US$ 0.3805 (-30.21%)	4.32M
AGFYAgrify Corporation	US$ 27.2093 (-29.80%)	260.84k
SHOTWSafety Shot Inc	US$ 0.11 (-26.67%)	1,000
CDTConduit Pharmaceuticals Inc	US$ 0.1243 (34.67%)	405.44M
AKTSAkoustis Technologies Inc	US$ 0.0995 (14.24%)	160.04M
NVDANVIDIA Corporation	US$ 144.33 (-1.07%)	126.36M
WORXSCWorx Corporation	US$ 2.15 (119.39%)	80.83M
ELABElevai Labs Inc	US$ 0.02015 (-5.84%)	60.3M